Skip to main content
. 2014 Sep 23;9(9):e108228. doi: 10.1371/journal.pone.0108228

Figure 2. Validation of TGM2 by immunohistochemical study.

Figure 2

TGM2 immunohistochemistry (IHC) was performed on 82 meningiomas from a different cohort (n = 82, WHO grade I = 58, grade II = 21, and grade III = 3). The IHC images represented high (A) and low (B) expression of TGM2, respectively. Scale bar  = 50 µm. (C) The quantification of TGM2 expression was expressed by percentage of TGM2-immunopositive cell per high power field (%HPF). The dot plot showed that TGM2 expression was abundant (positive in >50% of cells) in all grade II and III meningiomas. The TGM2 expression level was correlated with increased WHO malignancy grade (ANOVA, p = 0.0046). (D) The dot blot for TGM2 expression in grade I meningiomas revealed that those tumors with recurrence had high TGM2 expression (positive in >70% of cells).